MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Summit Therapeutics PLC Company Profile (NASDAQ:SMMT)

Consensus Ratings for Summit Therapeutics PLC (NASDAQ:SMMT) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.33 (159.53% upside)

Analysts' Ratings History for Summit Therapeutics PLC (NASDAQ:SMMT)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/25/2016OppenheimerReiterated RatingOutperform$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2015Needham & Company LLCReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015JMP SecuritiesInitiated CoverageOutperform$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha